【摘要】 帕金森病（Parkinson’s disease,PD）是第二大神经退行性疾病，α-突触核蛋白（α-synuclein,α-syn）的病理性聚集体是PD的生物标志物，与PD的发生发展密切相关。寻找一种在疾病早期就能够抑制病理性聚集体如α-syn寡聚体与α-syn原纤维形成的抑制剂，对治疗PD具有重要意义。近年来以α-syn为靶点的聚集抑制剂研究有了显著进展。文章综述了α-syn的结构、生理功能、病理机制和聚集抑制剂的研究进展，旨在为α-syn聚集抑制剂进一步研发提供参考。更多还原

【Abstract】 Parkinson’s disease(PD)is the second most common neurodegenerative disease. The pathological aggregation of α-synuclein(α-syn)is a biomarker of PD,which is closely related to the occurrence and development of PD. Finding an inhibitor that can inhibit the formation of pathological aggregates such as α-syn oligomer and α-syn protofibrils at the early stage of the disease is of great significance for the treatment of PD. In recent years,significant progress has been made in the research of inhibitors targeting α-syn aggregation. This review summarizes the structure,physiological function,pathological mechanism and inhibitors of α-syn aggregation,aiming to provide a reference for the further research and development of α-syn aggregation inhibitors.更多还原